New combo therapy shows promise for vitiligo patients
NCT ID NCT07251595
First seen Dec 10, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tests a new drug called SHR0302, given as a pill alone or with a gel, for people with non-segmental vitiligo (white patches on skin). The goal is to see if it can reduce the size of the patches, especially on the face. About 176 adults aged 18 to 75 will take part, and the study is double-blind and placebo-controlled, meaning some will get the real drug and some will get a dummy treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SEGMENTAL VITILIGO are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dermatology Hospital affiliated to Shandong First Medical University
RECRUITINGJinan, Shandong, 250022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.